Screening for Common Fetal Trisomies in Twin Pregnancies

First-Trimester Combined, Cell-Free DNA, or Both?

Lucia Pasquini, Ilaria Ponziani, Enrico Periti, Laura Marchi, Carlo Luchi, Veronica Accurti, Francesco D'Ambrosi, Nicola Persico

Research output: Contribution to journalArticle

Abstract

Objective: To examine the distribution of risks for fetal trisomies after first-trimester combined screening in twins and to investigate different strategies for clinical implementation of cell-free DNA (cfDNA) testing. Methods: We retrospectively analyzed all twin pregnancies undergoing first-trimester combined screening over a 10 years' period. The population was stratified according to various risk cut-offs, and we examined different screening strategies for implementation of cfDNA testing in terms of impact on invasive testing rate, cfDNA test failure rate, and economic costs. Results: We included 572 twin pregnancies: 480 (83.92%) dichorionic and 92 (16.08%) monochorionic. Performing a first-line combined screening and offering cfDNA testing to the group with a risk between 1 in 10 and 1 in 1,000, would lead to an invasive testing rate of 2.45%, and cfDNA testing would be performed in 22.20% of the population. This strategy would be cost-neutral compared to universal combined screening alone. Conclusions: First-trimester combined screening results can be used to stratify twin pregnancies into different risk categories and select those that could be offered cfDNA testing. A contingent screening strategy would substantially decrease the need for invasive testing in twins and it would be cost-neutral compared to combined testing alone.

Original languageEnglish
JournalFetal Diagnosis and Therapy
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Pregnancy Trimesters
Twin Pregnancy
Trisomy
First Pregnancy Trimester
DNA
Costs and Cost Analysis
Population
Economics

Keywords

  • Cell-free DNA
  • Chromosomal abnormalities
  • Combined test
  • First-trimester screening
  • Twin pregnancies

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Embryology
  • Radiology Nuclear Medicine and imaging
  • Obstetrics and Gynaecology

Cite this

Screening for Common Fetal Trisomies in Twin Pregnancies : First-Trimester Combined, Cell-Free DNA, or Both? / Pasquini, Lucia; Ponziani, Ilaria; Periti, Enrico; Marchi, Laura; Luchi, Carlo; Accurti, Veronica; D'Ambrosi, Francesco; Persico, Nicola.

In: Fetal Diagnosis and Therapy, 01.01.2018.

Research output: Contribution to journalArticle

Pasquini, Lucia ; Ponziani, Ilaria ; Periti, Enrico ; Marchi, Laura ; Luchi, Carlo ; Accurti, Veronica ; D'Ambrosi, Francesco ; Persico, Nicola. / Screening for Common Fetal Trisomies in Twin Pregnancies : First-Trimester Combined, Cell-Free DNA, or Both?. In: Fetal Diagnosis and Therapy. 2018.
@article{40aaf23b1cc7497d8f567dbcec7bde95,
title = "Screening for Common Fetal Trisomies in Twin Pregnancies: First-Trimester Combined, Cell-Free DNA, or Both?",
abstract = "Objective: To examine the distribution of risks for fetal trisomies after first-trimester combined screening in twins and to investigate different strategies for clinical implementation of cell-free DNA (cfDNA) testing. Methods: We retrospectively analyzed all twin pregnancies undergoing first-trimester combined screening over a 10 years' period. The population was stratified according to various risk cut-offs, and we examined different screening strategies for implementation of cfDNA testing in terms of impact on invasive testing rate, cfDNA test failure rate, and economic costs. Results: We included 572 twin pregnancies: 480 (83.92{\%}) dichorionic and 92 (16.08{\%}) monochorionic. Performing a first-line combined screening and offering cfDNA testing to the group with a risk between 1 in 10 and 1 in 1,000, would lead to an invasive testing rate of 2.45{\%}, and cfDNA testing would be performed in 22.20{\%} of the population. This strategy would be cost-neutral compared to universal combined screening alone. Conclusions: First-trimester combined screening results can be used to stratify twin pregnancies into different risk categories and select those that could be offered cfDNA testing. A contingent screening strategy would substantially decrease the need for invasive testing in twins and it would be cost-neutral compared to combined testing alone.",
keywords = "Cell-free DNA, Chromosomal abnormalities, Combined test, First-trimester screening, Twin pregnancies",
author = "Lucia Pasquini and Ilaria Ponziani and Enrico Periti and Laura Marchi and Carlo Luchi and Veronica Accurti and Francesco D'Ambrosi and Nicola Persico",
year = "2018",
month = "1",
day = "1",
doi = "10.1159/000494055",
language = "English",
journal = "Fetal Diagnosis and Therapy",
issn = "1015-3837",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Screening for Common Fetal Trisomies in Twin Pregnancies

T2 - First-Trimester Combined, Cell-Free DNA, or Both?

AU - Pasquini, Lucia

AU - Ponziani, Ilaria

AU - Periti, Enrico

AU - Marchi, Laura

AU - Luchi, Carlo

AU - Accurti, Veronica

AU - D'Ambrosi, Francesco

AU - Persico, Nicola

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: To examine the distribution of risks for fetal trisomies after first-trimester combined screening in twins and to investigate different strategies for clinical implementation of cell-free DNA (cfDNA) testing. Methods: We retrospectively analyzed all twin pregnancies undergoing first-trimester combined screening over a 10 years' period. The population was stratified according to various risk cut-offs, and we examined different screening strategies for implementation of cfDNA testing in terms of impact on invasive testing rate, cfDNA test failure rate, and economic costs. Results: We included 572 twin pregnancies: 480 (83.92%) dichorionic and 92 (16.08%) monochorionic. Performing a first-line combined screening and offering cfDNA testing to the group with a risk between 1 in 10 and 1 in 1,000, would lead to an invasive testing rate of 2.45%, and cfDNA testing would be performed in 22.20% of the population. This strategy would be cost-neutral compared to universal combined screening alone. Conclusions: First-trimester combined screening results can be used to stratify twin pregnancies into different risk categories and select those that could be offered cfDNA testing. A contingent screening strategy would substantially decrease the need for invasive testing in twins and it would be cost-neutral compared to combined testing alone.

AB - Objective: To examine the distribution of risks for fetal trisomies after first-trimester combined screening in twins and to investigate different strategies for clinical implementation of cell-free DNA (cfDNA) testing. Methods: We retrospectively analyzed all twin pregnancies undergoing first-trimester combined screening over a 10 years' period. The population was stratified according to various risk cut-offs, and we examined different screening strategies for implementation of cfDNA testing in terms of impact on invasive testing rate, cfDNA test failure rate, and economic costs. Results: We included 572 twin pregnancies: 480 (83.92%) dichorionic and 92 (16.08%) monochorionic. Performing a first-line combined screening and offering cfDNA testing to the group with a risk between 1 in 10 and 1 in 1,000, would lead to an invasive testing rate of 2.45%, and cfDNA testing would be performed in 22.20% of the population. This strategy would be cost-neutral compared to universal combined screening alone. Conclusions: First-trimester combined screening results can be used to stratify twin pregnancies into different risk categories and select those that could be offered cfDNA testing. A contingent screening strategy would substantially decrease the need for invasive testing in twins and it would be cost-neutral compared to combined testing alone.

KW - Cell-free DNA

KW - Chromosomal abnormalities

KW - Combined test

KW - First-trimester screening

KW - Twin pregnancies

UR - http://www.scopus.com/inward/record.url?scp=85057261481&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057261481&partnerID=8YFLogxK

U2 - 10.1159/000494055

DO - 10.1159/000494055

M3 - Article

JO - Fetal Diagnosis and Therapy

JF - Fetal Diagnosis and Therapy

SN - 1015-3837

ER -